SCHEMBL4577285

SCHEMBL4577285

COC(=O)CC[C@H](NC(C)=O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
THRB P10828 1/20 0.52
ALOX15 P16050 1/20 0.52
NFKB1 P19838 1/20 0.52
PTGS2 P35354 1/20 0.52
THPO P40225 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 2/20 0.50
FOLH1 Q04609 7/20 0.47
NAALAD2 Q9Y3Q0 2/20 0.47
RIMKLA Q8IXN7 1/20 0.47
SLC1A1 P43005 1/20 0.46
TSHR P16473 3/20 0.44
GNPAT O15228 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17715158 1.00 MAPT (0.52) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL28015219 0.86 FOLH1 (0.48) FOLH1NAALAD2RIMKLASLC1A1TSHR
SCHEMBL18849724 0.85 FOLH1 (0.47) FOLH1NAALAD2RIMKLASLC1A1TSHR
SCHEMBL463421 0.85 CA12 (0.48) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL468764 0.85 CA12 (0.48) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL21274418 0.84 L3MBTL1 (0.58) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL21274419 0.84 L3MBTL1 (0.58) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL11124589 0.84 L3MBTL1 (0.58) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL13379936 0.83 FOLH1 (0.46) FOLH1NAALAD2RIMKLASLC1A1TSHR
SCHEMBL10045845 0.82 SMN1; SMN2 (0.53) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5284872-A Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof SCHWARZ PHARMA AG (DE) 1994-02-08 US claimed
WO-2019202611-A1 AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS METROCHEM API PVT (IN) 2019-10-24 WO disclosed
EP-1414432-A4 METHODS OF USE FOR NOVEL SULFUR CONTAINING ORGANIC NITRATE COMPOUNDS NITROMED INC (US) 2008-01-09 EP disclosed
US-20040152753-A1 Methods of use for novel sulfur containing organic nitrate compounds NITROMED, INC. 2004-08-05 US disclosed
EP-1414432-A2 METHODS OF USE FOR NOVEL SULFUR CONTAINING ORGANIC NITRATE COMPOUNDS Nitromed, Inc. (US) 2004-05-06 EP disclosed
WO-2003013432-A2 METHODS OF USE FOR NOVEL SULFUR CONTAINING ORGANIC NITRATE COMPOUNDS NITROMED, INC. (US) 2003-02-20 WO disclosed
US-5284872-A Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof SCHWARZ PHARMA AG (DE) 1994-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152753-A1 Methods of use for novel sulfur containing organic nitrate compounds PTGS2, NOS2, PTGS1 MAPT 1688/4885KDM4E 4241/4885THRB 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.